RééDOC
75 Boulevard Lobau
54042 NANCY cedex

Christelle Grandidier Documentaliste
03 83 52 67 64


F Nous contacter

0

Article

--";3! O
     

-A +A

Drugs with potential cardiac adverse effects : Retrospective study in a large cohort of parkinsonian patients

HERANVAL A; LEFAUCHEUR R; FETTER D; ROUILLE A; LE GOFF F; MALTETE D
REV NEUROL (Paris) , 2016, vol. 172, n° 4-5, p. 318-23
Doc n°: 178999
Localisation : Documentation IRR

D.O.I. : http://dx.doi.org/DOI:10.1016/j.neurol.2015.11.007
Descripteurs : AF5 - PARKINSON, FA3 - CARDIOPATHIES

Traitements cardiotropes, complications cardiaques et maladie de Parkinson
Abstract : Drugs with potential cardiac adverse effects are commonly
prescribed in Parkinson's disease (PD). To describe demographic and clinical
characteristics in a group of PD patients with cardiac events and to evaluate risk factors. METHODS: We sampled 506 consecutive PD patients (211
women/295 men), median age 68.3+/-10.6 years (range 36-95) and median disease
duration 11.2+/-6.5 years (range 1-49). Medications with potential cardiac
effects, i.e. QT prolongation (citalopram, escitalopram, venlafaxine, sertraline,
domperidone, amantadine, solifenacin), ventricular arrhythmia (rivastigmine,
clozapine, midodrine, sildenafil, tadalafil) and ischemic heart disease
(rasagiline, entacapone, tadalafil) were recorded. Demographic and clinical data
were collected prospectively; cardiac events were obtained retrospectively.
RESULTS: Twenty-four patients (4.7%) (9 women/15 men) presented a cardiac event.
Fifteen (62.5%) patients had dysautonomia, 4 (16.6%) a history of heart disease
and 8 (33.3%) were taking one or more drugs with a definite potential cardiac
adverse effect. Age (75.9+/-6.6 yr vs. 67.8+/-11 yr), disease duration
(14.7+/-3.6 yr vs. 11+/-6.5 yr), dysautonomia (62.5% vs. 24.5%) and dementia
associated with PD (37.5% vs. 14.6%) were significantly higher in the group with
cardiac events (P<0.05). Cofactors increasing the risk for cardiovascular events
were age and dysautonomia. CONCLUSION: Our results indicate that the
neurodegenerative process in Parkinson's disease is associated with a higher risk
of cardiovascular complications.
CI - Copyright (c) 2016 Elsevier Masson SAS. All rights reserved.

Langue : ANGLAIS

Mes paniers

4

Gerer mes paniers

0